Absci Q3 Revenue Misses Estimates by More Than Half at $304K
ABSI has more than doubled off its 52-week low of $2.24.
Summary
Absci posted Q3 revenue of $304 thousand against an IBES estimate of $727.1 thousand — a miss of more than half. The loss was wide: net income of -$33.3 million, operating income of -$34.994 million, and basic EPS of -$0.19, with operating expenses at $35.298 million. For a company with a roughly $1.7 billion market cap and no product revenue yet, the top-line shortfall matters less than the burn rate; the Q2 10-Q said cash runway extends into the second half of 2028, so this quarter's spend needs to be read against that runway. The revenue miss is a negative data point for a story that trades on pipeline progress, not quarterly sales.
At the time of this announcement, ABSI was trading at $9.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $2.24 to $12.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.